Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents
Authors: Xin-Lin Zhang, Biao Xu
Journal: Annals of Internal Medicine (2016)

Letters6 December 2016Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic StentsXin-Lin Zhang, MD and Biao Xu, MD, PhDXin-Lin Zhang, MDFrom Affiliated Drum Tower Hospital and Nanjing University School of Medicine, Nanjing, China.Search for more papers by this author and Biao Xu, MD, PhDFrom Affiliated Drum Tower Hospital and Nanjing University School of Medicine, Nanjing, China.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0419 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We agree with Dr. Shah that observational data are less reliable than those from RCTs for providing evidence of cause and effect because of residual confounding even after statistical adjustments. As such, we did not definitively conclude that BVSs increase the incidence of stent thrombosis or myocardial infarction compared with EESs, although this nonsignificance in RCTs was probably due to our analyses' lack of power to detect differences of rare events. Thus, results of large-scale RCTs are critically needed to confirm these findings. However, we believe that observational studies from real-world practice are important complements to randomized trials.... References1. de Ribamar Costa J, Abizaid A. Long-term outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials [Abstract]. J Am Coll Cardiol. 2016;67 13 SUPPL 1 430. doi:10.1016/S0735-1097(16)30431-4 CrossrefGoogle Scholar2. Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67:921-31. [PMID: 26916481] doi:10.1016/j.jacc.2015.12.019 CrossrefMedlineGoogle Scholar3. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905-15. [PMID: 26457558] doi:10.1056/NEJMoa1509038 CrossrefMedlineGoogle Scholar4. Kereiakes DJ, Onuma Y, Serruys PW, Stone GW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation. 2016;134:168-82. [PMID: 27400899] doi:10.1161/CIRCULATIONAHA.116.021539 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Affiliated Drum Tower Hospital and Nanjing University School of Medicine, Nanjing, China.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-0006. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents Xin-Lin Zhang , Li Zhu , Zhong-Hai Wei , Qing-Qing Zhu , Jian-Zhong Qiao , Qing Dai , Wei Huang , Xiao-Hong Li , Jun Xie , Li-Na Kang , Lian Wang , and Biao Xu Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents Rahman Shah Metrics 6 December 2016Volume 165, Issue 11Page: 829KeywordsDisclosureInflammationInterventional cardiologyLesionsMyocardial infarctionObservational studiesRandomized trialsStatistical dataStent implantationThrombosis ePublished: 6 December 2016 Issue Published: 6 December 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...